Targeting the calcineurin-NFAT protein-protein interaction rather than enzyme active sites, this project develops a novel class of inhibitors to treat steroid-refractory ulcerative colitis with fewer side effects.
Using cancer patients experiencing immunotherapy-triggered autoimmunity as a unique human model, this project uncovers the molecular and epigenetic mechanisms by which self-reactive T cells escape immune tolerance.
Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.
Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Developing T cell-redirecting bispecific antibodies to selectively eliminate tuft cells and break the cycle of Type 2 inflammation in CRSwNP.
Developing an IFNγ-based molecular microscope to assess celiac disease activity and response to treatment without relying solely on diagnostic biopsies.
Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.
Developing and validating a humanized MISTRG6 mouse model that accurately replicates human immune responses to gluten for celiac disease research and drug development.
Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
